22 January 2015 : Original article
Donor Hepatitis C Sero-Status does not Impact Survival in Liver Transplantation
Martin I. MontenovoABDEF, Andre A.S. DickADE, Ryan N. HansenABCDEGDOI: 10.12659/AOT.892530
Ann Transplant 2015; 20:44-50
Abstract
BACKGROUND: Liver disease caused by hepatitis C virus (HCV) is the main indication for liver transplantation (LT) among adults in the US. Recurrent HCV impairs patient and graft survival after LT. The high prevalence of HCV along with scarce organs has lead to increased utilization of HCV+ organs. We estimated the impact of HCV+ donors on patient and graft survival.
MATERIAL AND METHODS: We conducted a cohort study of LT recipients age 18 years or older from February 2002 through December 2012 utilizing UNOS data. We evaluated differences in patient characteristics between HCV+ and HCV- recipients. We also compared patient and graft survival between these groups and among HCV+ recipients who received HCV+ versus HCV- donor organs using the Kaplan-Meier estimator and multivariate stratified Cox regression models.
RESULTS: We identified 59,899 LT recipients. Among those, 1,695 (2.8%) were HCV+ who received HCV+ grafts. HCV+ recipients of HCV- grafts were more likely to be female, hospitalized, in the ICU, on a ventilator, had higher MELD scores, and higher bilirubin. Patient and graft survival at 1, 5, and 10 years in HCV+ recipients was inferior to HCV– recipients, but HCV+ recipients who received HCV+ versus HCV– grafts were equivalent. Multivariate regression revealed multiple variables associated with worse outcomes.
CONCLUSIONS: The use of HCV+ grafts in HCV+ recipients is not associated with worse outcomes. With the increase in HCV+ patients awaiting an organ, more consideration should be given to HCV+ donors.
Keywords: Hepatitis C, Liver Transplantation, Survival
In Press
Original article
CD146⁺ Endothelial Cells Facilitate Renal Interstitial Fibrosis Through Endothelial-to-Mesenchymal TransitionAnn Transplant In Press; DOI: 10.12659/AOT.945917
Original article
Effect of Medical Accessibility on Long-Term Survival in Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.944839
Most Viewed Current Articles
05 Apr 2022 : Original article 13,217
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 10,665
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
12 Jan 2022 : Original article 9,806
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
15 Mar 2022 : Case report 7,520
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860